oate:Oct. 27 th , 2021
our Name:Wei Huang
Nanuscript Title: A narrative review of liver regeneration—from models to molecular basis
Januscript number (if known): ATM-21-5234

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Wei HuangNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	Wei HuangNone	
4	Consulting fees	Wei Huang None	

5	Payment or honoraria for lectures, presentations,	Wei Huang None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	Wei Huang None	
7	Support for attending meetings and/or travel	Wei Huang None	
8	Patents planned, issued or	Wei Huang None	
	pending		
9	Participation on a Data	Wei Huang None	
	Safety Monitoring Board or		
-10	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	Wei HuangNone	
12	Receipt of equipment,	Wei Huang None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dlooco	summarize	the shows	conflict o	fintaract	in tha	following	hav.
PIPASP	Summarize	the annve	CONTILCT O	TINTEREST	IN THE	thiihwing	UUX.

None			
1101101			

Please place an "X" next to the following statement to indicate your agreement:

Date:Oct. 27 ^{tn} , 2021	
Your Name: Ning Han_	_
Manuscript Title:A	narrative review of liver regeneration—from models to molecular basis
Manuscript number (if kno	own): ATM-21-5234

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Ning HanNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Ning Han None	
3	Royalties or licenses	Ning HanNone	
4	Consulting fees	Ning HanNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Ning Han None	
6	Payment for expert testimony	Ning Han None	
7	Support for attending meetings and/or travel	Ning Han None	
8	Patents planned, issued or pending	Ning Han None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Ning Han None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Ning Han None	
11	Stock or stock options	Ning Han None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ning Han _None	
13	Other financial or non- financial interests	Ning Han None	

None			
1101101			

Please place an "X" next to the following statement to indicate your agreement:

Date:Oct. 2	7 th , 2021
Your Name:Li	ngyao Du
Manuscript Title:	A narrative review of liver regeneration—from models to molecular basis
Manuscrint numb	er (if known): ATM-21-5234

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Lingyao Du _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for ectures, presentations,	Lingyao Du _None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Lingyao DuNone	
8	Patents planned, issued or pending	Lingyao DuNone	
9	Participation on a Data Safety Monitoring Board or	<u>Lingyao Du</u> None	
	Advisory Board		
10	Leadership or fiduciary role	Lingyao DuNone	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	Lingyao Du None	
11	Stock of Stock options	Liligyao DuNone	
12	Receipt of equipment, materials, drugs, medical	Lingyao Du _None	
	writing, gifts or other services		
13	Other financial or non-	Lingyao Du None	
	financial interests		

None			
1101101			

Please place an "X" next to the following statement to indicate your agreement:

Date:	Oct. 27 th , 2021	
Your Name	:Ming Wang	
Manuscript	Title: A narrative review of liver regeneration—from models to molecular basis	_
Manuscript	number (if known): ATM-21-5234	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the ini	Specifications/Comments (e.g., if payments were made to you or to your institution) tial planning of the work
1	All support for the present	Ming WangNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: pa	ast 36 months
2	Grants or contracts from	Ming WangNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	Ming WangNone	
4	Consulting fees	Ming Wang_ None	

5	Payment or honoraria for	Ming Wang_	_None	
	lectures, presentations, speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	Ming Wang_	_None	
	testimony			
7	Support for attending	Ming Wang	None	
′	meetings and/or travel	Ming Wang_	ivone	
	-			
8	Patents planned, issued or	Ming Wang_	None	
	pending			
9	Participation on a Data	_Ming Wang_	None	
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	Ming Wang_	None	
10	in other board, society,	ivillig_vvalig	None	
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	Ming Wang_	None	
12	Receipt of equipment,	Ming Wang_	None	
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	Ming Wang_	None	
	financial interests			

Please place an "X" next to the following statement to indicate your agreement:

Date:Oct. 2	7 th , 2021
Your Name:Li	yu Chen
Manuscript Title:	A narrative review of liver regeneration—from models to molecular basis
Manuscript numb	er (if known): ATM-21-5234

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Liyu ChenNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Liyu ChenNone	
3	Royalties or licenses	Liyu Chen _None	
4	Consulting fees	Liyu ChenNone	

5	Payment or honoraria for	Liyu ChenNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Liyu ChenNone	
	testimony		
7	Support for attending	<u>Liyu Chen</u> None	
	meetings and/or travel		
8	Patents planned, issued or	Liyu Chen _None	
	pending		
9	Participation on a Data	_Liyu Chen None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Liyu Chen None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_Liyu Chen None	
12	Receipt of equipment,	Liyu Chen _None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_Liyu Chen None	
_	financial interests		

None			
1101101			

Please place an "X" next to the following statement to indicate your agreement:

Date:Oct. 2	7 th , 2021
Your Name:Ho	ong Tang
Manuscript Title:	A narrative review of liver regeneration—from models to molecular basis
Manuscrint numb	er (if known): ATM-21-5234

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Hong Tang None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Hong Tang None	
3	Royalties or licenses	Hong Tang None	
4	Consulting fees	Hong Tang None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Payment for expert for attending meetings and/or travel Phong Tang None				
speakers bureaus, manuscript writing or educational events 6	5		Hong Tang None	
manuscript writing or educational events Payment for expert testimony To Support for attending meetings and/or travel Hong Tang None Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Hong Tang None Hong Tang None		· •		
educational events Payment for expert testimony Support for attending meetings and/or travel Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical writing, gifts or other services Hong Tang None		•		
testimony Support for attending meetings and/or travel Hong Tang None Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Hong Tang None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None	6	·	Hong Tang _None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None		testimony		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None Hong Tang None Hong Tang None Hong Tang None	7		Hong Tang None	
Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None Hong Tang None Hong Tang None Hong Tang None		meetings and/or travei		
Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Hong Tang None Hong Tang None Hong Tang None Hong Tang None Tang None Hong Tang None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Hong Tang None	8		Hong TangNone	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Hong Tang None Hong Tang None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None Hong Tang None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Hong Tang None Hong Tang None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None Hong Tang None				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Hong Tang None Hong Tang None Hong Tang None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None Hong Tang None	9		Hong TangNone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Hong Tang None Hong Tang None Hong Tang None Hong Tang None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None Hong Tang None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Hong TangNone 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong TangNone Hong TangNone	10	•	Hong Tang None	
group, paid or unpaid 11 Stock or stock options Hong TangNone 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong TangNone Hong TangNone	10		None	
11 Stock or stock options Hong TangNone 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong TangNone Hong TangNone		-		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong TangNone				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None	11	Stock or stock options	Hong TangNone	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- Hong Tang None	12	Receipt of equipment,	Hong Tang None	
services 13 Other financial or non- Hong Tang None		materials, drugs, medical		
	13	Other financial or non-	Hong Tang None	
		financial interests		

Please summarize	the a	bove co	onflict	t of i	nterest	t in t	:he 1	fol	lowing	box:
------------------	-------	---------	---------	--------	---------	--------	-------	-----	--------	------

l			
None			
1101101			

Please place an "X" next to the following statement to indicate your agreement: